Literature DB >> 35184686

Ultrasound-targeted microbubble destruction-mediated miR-144-5p overexpression enhances the anti-tumor effect of paclitaxel on thyroid carcinoma by targeting STON2.

Xuefeng Chen1,2, Xinyuan Zhang2, Yangyang Qian3, Enhui Xia2, Yu Wang4, Qi Zhou1.   

Abstract

The effects of miR-144-5p and paclitaxel (PTX) on thyroid carcinoma were less explored. Thus, we investigated the effects of miR-144-5p and PTX on thyroid carcinoma. The expression and target gene of miR-144-5p in thyroid carcinoma were analyzed by bioinformatics, y qRT-PCR and dual-luciferase reporter assay. After the transfection mediated by ultrasound-targeted microbubble destruction (UTMD) or liposome, or the treatment of PTX, the viability, proliferation, migration, and invasion of thyroid carcinoma cells were detected by MTT, colony formation, wound-healing, and transwell assays. The expressions of miR-144-5p, STON2, MMP-9, E-cadherin, and N-cadherin in cells were calculated via qRT-PCR or Western blotting. After a subcutaneous-xenotransplant tumor model was established using BALB/c nude mice and further treated with PTX and UTMD-mediated miR-144-5p, the volume, weight, and Ki67 level of tumor were recorded or evaluated by immunohistochemical assays. MiR-144-5p, which was low-expressed in thyroid carcinoma, directly down-regulated STON2 level. MiR-144-5p overexpression and PTX inhibited the viability, proliferation, migration, and invasion of thyroid carcinoma cells, while miR-144-5p silencing caused the opposite results. MiR-144-5p overexpression and PTX further up-regulated E-cadherin level and down-regulated those of MMP-9 and N-cadherin in thyroid carcinoma cells. STON2 overexpression reversed the effects of miR-144-5p overexpression.. MiR-144-5p overexpression enhanced the inhibiting effect of PTX on tumor volume, weight, and Ki67 level of xenotransplant tumor, and the effects of UTMD-mediated miR-144-5p overexpression were stronger than those mediated by liposome. Collectively, UTMD-mediated miR-144-5p overexpression enhanced the anti-tumor effect of PTX on thyroid carcinoma by targeting STON2.

Entities:  

Keywords:  STON2; Thyroid carcinoma; miR-144-5p; paclitaxel; ultrasound-targeted microbubble destruction

Mesh:

Substances:

Year:  2022        PMID: 35184686      PMCID: PMC9037415          DOI: 10.1080/15384101.2022.2040778

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   5.173


  46 in total

1.  Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer.

Authors:  Cecilia L Speyer; Miriam A Bukhsh; Waris S Jafry; Rachael E Sexton; Sudeshna Bandyopadhyay; David H Gorski
Journal:  Breast Cancer Res Treat       Date:  2017-08-05       Impact factor: 4.872

2.  Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.

Authors:  S Filetti; C Durante; D Hartl; S Leboulleux; L D Locati; K Newbold; M G Papotti; A Berruti
Journal:  Ann Oncol       Date:  2019-12-01       Impact factor: 32.976

3.  Clinical trial of weekly paclitaxel chemotherapy for papillary thyroid carcinoma with squamous cell carcinoma component.

Authors:  Yasuhiro Ito; Takuya Higashiyama; Mitsuyoshi Hirokawa; Mitsuhiro Fukushima; Minoru Kihara; Yuuki Takamura; Kaoru Kobayashi; Akihiro Miya; Akira Miyauchi
Journal:  Endocr J       Date:  2012-06-03       Impact factor: 2.349

4.  Tim-3 promotes cell aggressiveness and paclitaxel resistance through NF-κB/STAT3 signalling pathway in breast cancer cells.

Authors:  Yizi Cong; Yuxin Cui; Shiguang Zhu; Jianqiao Cao; Haidong Zou; Tracey A Martin; Guangdong Qiao; Wenguo Jiang; Zhigang Yu
Journal:  Chin J Cancer Res       Date:  2020-10-31       Impact factor: 5.087

5.  TRAP1 regulates cell cycle and apoptosis in thyroid carcinoma cells.

Authors:  Giuseppe Palladino; Tiziana Notarangelo; Giuseppe Pannone; Annamaria Piscazzi; Olga Lamacchia; Lorenza Sisinni; Girolamo Spagnoletti; Paolo Toti; Angela Santoro; Giovanni Storto; Pantaleo Bufo; Mauro Cignarelli; Franca Esposito; Matteo Landriscina
Journal:  Endocr Relat Cancer       Date:  2016-07-15       Impact factor: 5.678

6.  INHIBITOR OF THE TRANSCRIPTION FACTOR NF-κB, DHMEQ, ENHANCES THE EFFECT OF PACLITAXEL ON CELLS OF ANAPLASTIC THYROID CARCINOMA IN VITRO AND IN VIVO.

Authors:  V V Pushkarev; D V Starenki; V M Pushkarev; O I Kovzun; M D Tronko
Journal:  Ukr Biochem J       Date:  2015 May-Jun

Review 7.  Application of Ultrasound-Targeted Microbubble Destruction-Mediated Exogenous Gene Transfer in Treating Various Renal Diseases.

Authors:  Shuaishuai Huang; Yu Ren; Xue Wang; Lissy Lazar; Suya Ma; Guobin Weng; Jinshun Zhao
Journal:  Hum Gene Ther       Date:  2018-10-31       Impact factor: 5.695

8.  Tumour-suppressive microRNA-144-5p directly targets CCNE1/2 as potential prognostic markers in bladder cancer.

Authors:  R Matsushita; N Seki; T Chiyomaru; S Inoguchi; T Ishihara; Y Goto; R Nishikawa; H Mataki; S Tatarano; T Itesako; M Nakagawa; H Enokida
Journal:  Br J Cancer       Date:  2015-06-09       Impact factor: 7.640

9.  Effect of miR-144-5p on the proliferation, migration, invasion and apoptosis of human umbilical vein endothelial cells by targeting RICTOR and its related mechanisms.

Authors:  Wei Fu; Zidong Liu; Jing Zhang; Yuxue Shi; Ruiyao Zhao; Heng Zhao
Journal:  Exp Ther Med       Date:  2019-12-23       Impact factor: 2.447

10.  Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer.

Authors:  Giandomenico Roviello; Monica Ramello; Martina Catalano; Alberto D'Angelo; Raffaele Conca; Silvia Gasperoni; Lorenzo Dreoni; Roberto Petrioli; Anna Ianza; Stefania Nobili; Michele Aieta; Enrico Mini
Journal:  Sci Rep       Date:  2020-11-06       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.